Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER versus ULTRACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER versus ULTRACEF.
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER vs ULTRACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Cefadroxil, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis. It is bactericidal against susceptible organisms.
750 mg to 1.5 g intravenously every 8 hours; for severe infections, up to 1.5 g every 6 hours.
250 mg orally every 6 hours or 500 mg orally every 12 hours for uncomplicated urinary tract infections; 1 g orally every 12 hours for complicated urinary tract infections.
None Documented
None Documented
Terminal elimination half-life: 1.2-1.6 hours (prolonged to 15-22 hours in severe renal impairment, CrCl <10 mL/min); requires dose adjustment in renal failure
0.5–1.2 hours in normal renal function; prolonged to 2–4 hours in severe renal impairment (CrCl <10 mL/min).
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; fecal: <1%
Approximately 90% of an oral dose is excreted unchanged in urine via glomerular filtration and tubular secretion; less than 1% is excreted in feces via biliary elimination.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic